|
Real-time Estimate
Cboe BZX
04:04:32 2026-08-25 pm EDT
|
5-day change | 1st Jan Change | ||
| 549.00 USD | +0.26% |
|
+4.80% | +22.10% |
| Aug. 12 | Vertex Has Multiple Portfolio Catalysts With Favorable Risk-Reward, RBC Says | MT |
| Aug. 11 | Jefferies Adjusts Price Target on Vertex Pharmaceuticals to $633 From $610, Maintains Buy Rating | MT |
Company Valuation: Vertex Pharmaceuticals Incorporated
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 55,834 | 74,127 | 104,849 | 103,707 | 115,026 | 138,793 | - | - |
| Change | - | 32.76% | 41.44% | -1.09% | 10.91% | 20.66% | - | - |
| Enterprise Value (EV) 1 | 48,309 | 63,349 | 93,630 | 97,591 | 108,418 | 123,116 | 119,691 | 113,595 |
| Change | - | 31.13% | 47.8% | 4.23% | 11.09% | 13.56% | -2.78% | -5.09% |
| P/E | 24.4x | 22.5x | 29.3x | -194x | 29.6x | 32.3x | 26.4x | 21.9x |
| PBR | 5.53x | 5.33x | 5.96x | 6.4x | 6.17x | 6.18x | 5.13x | 4.23x |
| PEG | - | 0.5x | 3.51x | 2x | -0x | 3x | 1.2x | 1.1x |
| Capitalization / Revenue | 7.37x | 8.3x | 10.6x | 9.41x | 9.58x | 10.5x | 9.49x | 8.46x |
| EV / Revenue | 6.38x | 7.09x | 9.49x | 8.86x | 9.03x | 9.33x | 8.19x | 6.93x |
| EV / EBITDA | 10.8x | 12.8x | 20.6x | 108x | 19.8x | 21.1x | 17.4x | 14.3x |
| EV / EBIT | 11.1x | 13.2x | 21.4x | 140x | 20.6x | 22x | 18.2x | 14.5x |
| EV / FCF | 20.1x | 16.1x | 28.1x | -123x | 33.9x | 27.7x | 21.2x | 15.2x |
| FCF Yield | 4.99% | 6.2% | 3.56% | -0.81% | 2.95% | 3.61% | 4.72% | 6.56% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 9.01 | 12.82 | 13.89 | -2.08 | 15.32 | 16.96 | 20.73 | 25.05 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 7,574 | 8,931 | 9,869 | 11,020 | 12,001 | 13,195 | 14,619 | 16,399 |
| EBITDA 1 | 4,470 | 4,941 | 4,556 | 902.8 | 5,473 | 5,837 | 6,866 | 7,956 |
| EBIT 1 | 4,344 | 4,793 | 4,375 | 695.6 | 5,263 | 5,597 | 6,574 | 7,821 |
| Net income 1 | 2,342 | 3,322 | 3,620 | -535.6 | 3,953 | 4,306 | 5,228 | 6,392 |
| Net Debt 1 | -7,525 | -10,778 | -11,218 | -6,116 | -6,608 | -15,676 | -19,102 | -25,197 |
| Reference price 2 | 219.60 | 288.78 | 406.89 | 402.70 | 453.36 | 547.59 | 547.59 | 547.59 |
| Nbr of stocks (in thousands) | 254,252 | 256,691 | 257,683 | 257,529 | 253,719 | 253,461 | - | - |
| Announcement Date | 1/26/22 | 2/7/23 | 2/5/24 | 2/10/25 | 2/12/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 32.29x | 9.33x | 21.09x | -.--% | 139B | |
| 35.49x | 12.87x | 26.08x | 0.56% | 1,111B | |
| 30.37x | - | - | 1.97% | 658B | |
| 33.76x | 7.81x | 16.23x | 2.59% | 467B | |
| 20.64x | 4.89x | 12.12x | 2.7% | 369B | |
| 22.46x | 5.78x | 14.33x | 2.76% | 301B | |
| 21.25x | 4.36x | 12.44x | 2.02% | 256B | |
| 28.07x | 7.23x | 12.84x | 2.27% | 240B | |
| 13.6x | 4.83x | 10.09x | 3.78% | 207B | |
| -44.84x | 6.47x | 25.28x | 2.25% | 182B | |
| Average | 19.31x | 7.06x | 16.72x | 2.09% | 392.98B | |
| Weighted average by Cap. | 25.67x | 8.50x | 18.72x | 1.83% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- VRTX Stock
- Valuation Vertex Pharmaceuticals Incorporated
Select your edition
All financial news and data tailored to specific country editions
